June 7, 2010 (Chicago) -- Long-term treatment with the cancer drug Avastin may help keep advanced ovarian cancer in check, a study of more than 1,800 women suggests.
Women who took Avastin during standard chemotherapy and for up to 10 months afterward lived for about four months longer -- without signs of cancer growth -- than women who received chemotherapy alone.
Put another way, taking Avastin during and after chemo reduced the risk of cancer progression by 28% over chemo alone, says Robert A. Burger, MD, director of the Women’s Cancer Center at Fox Chase Cancer Center in Philadelphia.
Specifically, women who continued on "maintenance therapy" with Avastin, following Avastin and chemotherapy, showed no worsening of their disease for an average of 14.1 months. That compares with 10.3 months for women on chemo alone.
A third group of women in the study took Avastin only during chemotherapy. They lived an average of 11.2 months before their cancer progressed, a difference that was not significantly different than chemo alone.
Burger presented results of the study at annual meeting of the American Society of Clinical Oncology.
Avastin, which cuts off the supply of nutrient-rich blood to tumors, is already used to treat breast, lung, and colorectal cancers, typically in combination with chemotherapy.
Smaller trials showed promising activity in patients with recurrent ovarian cancer, Burger says.
The new study involved 1,873 women who had undergone surgery for newly diagnosed stage III or IV ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
One group received the standard chemotherapy combo of carboplatin and paclitaxel. Another group received Avastin plus the same chemotherapy drugs, followed by Avastin maintenance therapy. A third group received concurrent chemotherapy and Avastin, but no maintenance treatment.
Long-term Avastin therapy did bring more side effects. Nearly 23% of women developed moderate or serious high blood pressure, compared with 7.6% of women on chemo alone. A total of 2.6% of women developed moderate to severe bleeding, perforated intestines, or other serious gastrointestinal (GI) side effects, compared with 1.2% of women getting chemotherapy alone.